Not misconstrued, neither misunderstood. Your words: "the...

Not misconstrued, neither misunderstood. Your words: "the speculation of the TGA approval seems to be the reason this company is getting the attention for traders, short, mid and long term investors... no TGA approval for the EuGeni Reader means what for the company?".

You intimate that this recent sell off and poor market sentiment is due to ADO failing TGA approval and missing the Covid-boat as the virus turns endemic. You fail to acknowledge a large number of (emotional) holders were appalled and stunned by the lack of disclosure and poor leadership. Clear communication showing concise pathways was what we were wanting. There were always going to be hurdles. As the company pointed out, the normal timeline for bringing a similar product to market is around 5 years. No one expected it overnight. The problem arose when we were given timelines, missed those timelines and not disclosed the reasons why. It really is a simply issue of the market being continually informed and management being proactive rather than reactive. It probably would have meant less wild speculation and a more stable share price.

You refer to TGA approval as seemingly the only thing holding this stock up. That is misleading. It has a pipeline of tests planned and currently in development. You make the assumption that the market only values Eugeni for the standalone Covid test, but you forget that the first proof-of-concept was indeed the multiplex Covid/Flu. And it was the Sepsis multiplex test that was the first announced to market. The SP rerated considerably on the back of these announcements. Also, TGA approval was only sought in Sept last year. Plenty of wild SP action prior to that.

As for batteries, this could likely be a left field development - they are making progress and have significant IP. One sure fire way to get a position on that value is to hold this stock - and not trade it for the swings. Each to their own though. This is of course a speculative stock. It will be until it has significant revenue that keeps the bills paid and allows for future growth. How many other tech or biotech or even exploration start-ups have wildly unjustifiable market caps? ADO is not alone. This doesn't mean that they wont convert. And doesn't mean shareholders can't be disappointed in management for failure in disclosure and effective leadership.

And Mr Gold, I don't need to justify my own holding. Just trying to offer a different perspective to those that trade, pump, dump and sit on the fence. How many cap raises have you propped this company up with?